NDAORALCAPSULE, EXTENDED RELEASE
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VERELAN PM (verapamil hydrochloride) by R-Pharm US is (l-type calcium channel blocker or calcium channel antagonist). First approved in 1998.
Drug data last refreshed 13h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Verelan PM is an extended-release oral capsule formulation of verapamil hydrochloride, an L-type calcium channel blocker used to treat hypertension and angina. It works by selectively inhibiting calcium ion influx into vascular smooth muscle and cardiac cells, reducing contractility and blood pressure. The extended-release formulation provides once-daily dosing for improved patient compliance.
$0.12BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Medicare claims volume signals a mature brand facing generic erosion; commercial team focus shifts to generic transition planning.
Mechanism of Action
(L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Verelan PM offers experience managing a legacy cardiovascular asset through loss of exclusivity, requiring expertise in generic transition, market access optimization, and maintaining market share in a highly competitive space. Roles emphasize operational efficiency, compliance, and defensive strategy rather than innovation and growth.
Worked on VERELAN PM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.